Afonso-de-León JA, Sánchez-Barrera O, Rodríguez-Curbelo M, García-García D, Cañete-Villafranca R

Language: Spanish
References: 12
Page: 1691-1696
PDF size: 719.15 Kb.

ABSTRACT

To boost immunity in people with gradual deterioration of the immune system, caused by aging or suffering from different comorbidities, the Group of the Biotechnology and Pharmaceutical Industries of Cuba (Biotechnology Farma) has introduced the product Biomodulin T. This has also been used as part of the prevention protocol and for the treatment of patients positive to SARS-CoV-2. Thymus-dependent immunity, including T-cell immunity and antibody production, decreases with organ size in adults, which is known as “immunosenescence.” Biomodulin T is a diafiltered extract of veal thymus; it has a cytorestaurative and immunomodulatory action, which has demonstrated its effectiveness in different risk groups, within which elder people occupy a special place. In the current national and international epidemiological situation its inclusion in the protocols of action is significant. The use of this medication in a vulnerable group, such as elder people, represents a hopeful horizon as progress is made in the production of safe and effective national vaccines.

REFERENCES

1. Ministerio de Salud Pública. Protocolo de actuación nacional para la COVID-19 [Internet]. La Habana: Ministerio de Salud Pública; 2020 [citado 03/02/2021].215 p. Disponible en: Disponible en: https://files.sld.cu/editorhome/files/2021/03/VERSION_FINAL_6_EXTENDIDA_PROTOCOLO_REVISADA_28_MARZO__2021.pdf

2. Díaz-Canel-Bermúdez M, Núñez-Jover J. Gestión gubernamental y ciencia cubana en el enfrentamiento a la COVID-19. Anales de la Academia de Ciencias de Cuba [Internet]. 2020 [citado 03/02/2021];10(2). Disponible en: Disponible en: http://www.revistaccuba.cu/index.php/revacc/article/view/881/893

3. Martínez-Díaz E, Pérez-Rodríguez R, Herrera-Martínez L, et al. La industria biofarmacéutica cubana en el combate contra la pandemia de COVID-19. Anales de la Academia de Ciencias de Cuba [Internet]. 2020 [citado 03/02/2021];10(2):[aprox. 12 p.]. Disponible en: Disponible en: http://www.revistaccuba.cu/index.php/revacc/article/view/906/894

4. BioCubaFarma. Medicamentos biológicos innovadores. La Habana: BioCubaFarma; 2020. 16 p.

5. Organización Mundial de la Salud. Uso de Biomodulina T para la prevención de infecciones, incluido COVID-19 en adultos mayores. Ensayo clínico de fase IV. Plataforma internacional de registro de ensayos clínicos [Internet]. Ginebra: OMS; 2020 [citado 03/02/2021]. 9 p. Disponible en: Disponible en: https://rpcec.sld.cu/ensayos/RPCEC00000310-Sp

6. Suárez-Formigo GM, Saavedra-Hernández D. Biomodulina T May Restore Immunity in Older Adults. Medicc Review [Internet]. 2020 [citado 03/02/2021];22(3):54-6. Disponible en: Disponible en: https://mediccreview.org/biomodulina-t-may-restore-immunity-in-older-adults/

7. Fulop T, Larbi A, Dupuis G, et al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol. 2018 Jan 10;8:1960. Citado en PubMed; PMID: 29375577.

8. Rodríguez-Martín RR, González-González O, Rodríguez-González C, et al. Biomodulina T (InmunyVital®) Restores T Cells and Helps Contain COVID-19. Front Immunol. 2020 Dec 9;11:606447. Citado en PubMed; PMID: 33362793.

9. Saavedra D, Fuertes SA, Suárez GM, et al. Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. Exp Gerontol. 2019 Sept;124:110633. Citado en PubMed; PMID: 31207285.

10. World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. Ginebra: World Health Organization; 2020 [citado 03/02/2021]. Disponible en: Disponible en: https://apps.who.int/iris/handle/10665/332196

11. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED). Biomodulina® T (fracción tímica). Rev Cubana Farm [Internet]. 2020 [citado 03/02/2021];53(3):e469. Disponible en: Disponible en: http://www.revfarmacia.sld.cu/index.php/far

12. Lara-Rodríguez RF, Rodríguez R, Vargas-Batista A, et al. Efectos adversos por el uso de la biomodulina T y la corticotropina en pacientes con esclerosis múltiple. Medisur [Internet]. 2007 [citado 03/02/2021];5(1):65-72. Disponible en: Disponible en: http://www.medisur.sld.cu/index.php/medisur/article/view/253